注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
TetraLogic Pharmaceuticals Corporation是一家从事临床阶段生物制药的公司。该公司专注于发现和发展肿瘤学、传染病和自身免疫性疾病中的小分子治疗药物。该公司的业务部门为肿瘤和传染病新型小分子治疗的鉴定与开发。该公司拥有“Birinapant”和“SHAPE”两个临床阶段候选产品。“SHAPE”是公司正在被开发用于局部治疗早期T型皮肤细胞淋巴瘤(CTCL)的组蛋白脱乙酰酶(HDAC)抑制剂。该公司同时在“SHAPE”中探索研究秃发症,一种自身免疫性皮肤病。“SHAPE”被授予针对T型皮肤细胞淋巴瘤的美国罕见药。“Birinapant”是一种模拟第二线粒体活化剂的小分子治疗剂,它可以导致细胞凋亡或细胞死亡。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Randall K. Johnson | 75 | - | Member of Scientific Advisory Board |
Michael Andreeff | - | - | Member of Clinical Advisory Board |
John Silke | - | - | Member of the Scientific Advisory Board |
David L. Vaux | - | - | Member of the Scientific Advisory Board |
Neal Rosen | 72 | - | Member of the Scientific Advisory Board |
Alan F. List | 67 | - | Member of Clinical Advisory Board |
Philip Agop Philip | - | - | Member of Clinical Advisory Board |
Daniel Haller | - | - | Member of Clinical Advisory Board |
Anthony G. Letai | - | - | Member of the Scientific Advisory Board |
Alexandre Zyngier | 53 | 2016 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核